Status: Prior Investments

Clinical trial site services company operating an integrated network of research sites in the Southeast United States.

Clinical-stage company developing transformative medicines that dramatically improve the lives of patients with life-altering immune diseases.

Completed reverse merger in 2023
Acquired by Novartis in 2025

Clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders.

Acquired by Incyte in 2024

Disruptive animal health provider delivering innovative diagnostic solutions to veterinarians and pet owners across the United States.

Acquired by a strategic in 2025

Clinical-stage biotechnology company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV).

Clinical-stage biotechnology company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.

Completed IPO in 2021

Clinical-stage biotechnology company pursuing the development of novel small molecules that target cancer through its dependency on stress support pathways.

Clinical-stage immuno-oncology company that aims to discover and develop potential best-in-class antibody therapies for the treatment of patients with cancer.

Clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease.

Completed IPO in 2021

Commercial-stage specialty pharmaceutical company focused on pain management and adjacent specialty therapeutics areas.

Acquired by Zydus in 2017